Working with Industry Partners
The Center for Bioelectrics' primary mission is to carry out scientific research that increases our understanding of the interaction of electromagnetic fields and ionized gases with biological systems, and to use this knowledge to optimize and develop applications in biotechnology, medical diagnostics and therapeutics. From time to time, research interests of Center faculty converge with an industrial entity seeking answers to similar scientific questions, and the opportunity for industry to sponsor research at the Center arises. The Center supports and welcomes industry-sponsored projects that promote scientific advancements and stimulate the effective use of new knowledge.
Pulse Biosciences
is a bioelectric medicine company focused on technology and products utilizing nanosecond electric pulses to treat a range of dermatologic conditions and tumors. The technology originated at the Frank Reidy Research Center for Bioelectrics at 51Ç鱨վ and in the labs of Professor Martin Gundersen in the Department of Electrical Engineering at the University of Southern California. The spinout of this bioelectrics technology to Pulse Biosciences was a first for 51Ç鱨վ and an example of a university-developed technology reaching the marketplace. Bioelectrics' pathbreaking work has been recognized as the most successful university-based initial public offering (IPO) in the stock market-ever and the largest single commercialization effort achieved at 51Ç鱨վ. The Pulse Bioesciences' IPO resulted in a revenue of approximately $41 million to 51Ç鱨վ and its inventors.
The CellFX® System is the first commercially available product to harness the distinctive advantages of Nano-Pulse Stimulation (NPS™) technology. Initial target applications are a range of dermatologic conditions that share high demand among patients and practitioners for improved outcomes. The CellFX® System has received FDA, CE mark and Health Canada approvals.
Ìý
From left to right: Engineering prototype developed at the Center, two models developed in the Pulse Biosciences' engineering lab and the final commercial CellFX® system
Sponsored Research
| PRINCIPAL INVESTIGATOR | TITLE | YEAR |
|---|---|---|
| CLAUDIA MURATORI | NANO-PULSE STIMULATION FOR TREATMENT OF DIABETIC SKIN & SOFT TISSUE MRSA INFECTI | 2021 |
| ANDREI PAKHOMOV | MECHANISMS UNDERLYING THE SENSITIVITY OF SMOOTH MUSCLE CELLS TO NPS | 2021 |
| ANDREI PAKHOMOV | MINIMIZING NEUROMUSCULAR EXCITATION FROM NPS ABLATION | 2019 |
| CLAUDIA MURATORI | ACTIVATION OF THE DENDRITIC CELL-T AXIS BY nsPEF TREATMENTS | 2019 |
| P. THOMAS VERNIER | INFLAMMASOME ACTIVATION, CYTOKINE RELEASE, AND CYTOTOXICITY IN RESPONSE TO nsPEF | 2019 |
| STEPHEN BEEBE | NANOPULSE STIMULATION & IMMUNE M51Ç鱨վLATORS TO ENHANCE ANTI- TUMOR IMMUNE RESPONSE | 2018 |
| ANDREI PAKHOMOV | PERIPHERAL NERVE STIMULATION WITH UNI-AND BIPOLAR NANOSECOND PULSES | 2018 |
| CLAUDIA MURATORI | NANOSECOND PULSE STIMULATION TO BOOST THE IMMUNOGENICITY OF TUMOR CELL DEATH | 2018 |
| SHU XIAO | NANOSECOND PULSING TOWARDS EXTREME FREQUENCY | 2018 |
| CLAUDIA MURATORI | INVESTIGATING CUTIBACTERIUM ACNES INACTIVATION BY NANOSECOND PULSE STIMULATION | 2018 |
| P. THOMAS VERNIER | HYDROXYL RADICAL GENERATION AND DENDRITIC CELL ACTIVATION | 2017 |
| CLAUDIA MURATORI | EXPLORING MULTIMODAL CANCER CELL DEATH INDUCED BY NPS IN VIVO | 2017 |
| SHU XIAO | TARGET ADIPOSE TISSUE IN THE TREATMENT OF OBESITY USING PPA | 2017 |
| CHRISTIAN ZEMLIN | COMPARING THE EFFICACIES OF NANOSECOND PULSED ELECTRIC FIELD ABLATION AND RF AB | 2017 |
| SIQI GUO | NSEPS AS AN ABLATION-INMMUNOTHERAPY FOR ADVANCED PANCREATIC CANCER | 2016 |
| STEPHEN BEEBE | MECHANISMS THAT INDUCE IMMUNOGENIC CELL DEATH | 2016 |
| CHRISTIAN ZEMLIN | ABLATING CARDIC TISSUE WITH NANOSECOND PULSE | 2016 |
| JOHN CATRAVAS | SYNERGISTIC ACTIONS OF NSPEF HSP90 INHIBITORS | 2016 |
| RICHARD HELLER | ELECTROBLATE TASK ORDER 1 | 2015 |
| OLGA PAKHOMOVA | ELECTROBLATE TASK ORDER 2 | 2015 |
| STEPHEN BEEBE | ELECTROBLATE TASK ORDER 3 | 2015 |
| ANDREI PAKHOMOV | ELECTROBLATE TASK ORDER 4 | 2015 |